Further solidifying 2025 as the year of updates to clinical frameworks, the European Association for the Study of Obesity released a new pharmacotherapy framework [3]
Eli Lilly priced FOUNDAYO comparably to the WEGOVY pill, with self-pay access starting at $149/month for the lowest dose, eligible commercial insurance patients paying as low as $25/month with savings cards, and Medicare Part D patients expected to access it for $50/month beginning July 1, 2026
L-Carnitine is a naturally occurring amino acid derivative that plays a key role in transporting fatty acids into the mitochondria, where they are converted into energy
Fat mass accounted for the substantial majority of total weight reduction (PMID 40609566)
C., Cavuolu, K., Yalin, E
One thing is certain: the obesity treatment landscape will never be the same